WO2012141502A2 - Controlled release type tablet containing aceclofenac - Google Patents
Controlled release type tablet containing aceclofenac Download PDFInfo
- Publication number
- WO2012141502A2 WO2012141502A2 PCT/KR2012/002769 KR2012002769W WO2012141502A2 WO 2012141502 A2 WO2012141502 A2 WO 2012141502A2 KR 2012002769 W KR2012002769 W KR 2012002769W WO 2012141502 A2 WO2012141502 A2 WO 2012141502A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- aceclofenac
- tablet
- release layer
- controlled release
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Definitions
- the present invention relates to an aceclofenac-containing controlled release tablet, which will be described in more detail, wherein the slow-release layer is composed of a multi-layer structure having a rapid-release layer and a slow-release layer.
- the present invention relates to aceclofenac-containing controlled release tablets containing polyethylene oxide, which are designed to be taken once daily while having a much smaller size than the conventional controlled release substrate.
- Aceclofenac is a nonsteroidal anti-inflammatory analgesic. It has better absorption in inflammatory tissues than other non-steroidal anti-inflammatory drugs, and has an excellent inhibitory effect on the production of the bioactive substance, prostagladin, which causes arthritis, spondylitis, toothache, and post-traumatic inflammation. It is known to be effective in low back pain, sciatica and postoperative pain.
- COX-2 is selectively blocked to reduce the production of prostaglandin, thereby reducing the side effects including gastrointestinal disorders and having high stability.
- aceclofenac preparations having such a pharmacological action tablets to be taken 100 mg twice a day and capsules to be taken twice a day to improve bioavailability are commercially available.
- aceclofenac oral solution is inconvenient to be taken twice daily at 12 hour intervals.
- sustained release preparations that can reduce the frequency of aceclofenac preparations.
- the sustained-release preparation is much larger than the rapid-release preparation, it has been a very important technical task to reduce the size of the sustained-release tablet as much as possible to improve the convenience of the patient.
- slow release tablets are also important to control the rate of release, but the technique of making the tablet size appropriate is more difficult and requires more research.
- Korean Patent Laid-Open Publication No. 2006-0117572 (published date; November 17, 2006) includes a controlled-release aceclofenac preparation that sustains drug efficacy for 24 hours with a once-daily administration. I introduce it.
- the formulation is 57 to 58.29% by weight of aceclofenac powder coated with ethyl cellulose; 14.28% by weight calcium monohydrogen phosphate; Lactose 24-25%; 2.86 wt% magnesium stearate; And 0.57% by weight of hard silicic anhydride.
- Korean Patent Publication No. 2010-0064015 (published date: June 14, 2010) is a rapid release layer containing aceclofenac, water-soluble additives, pH regulators, disintegrants, fillers and lubricants, and aceclofenac, a release control polymer , A controlled release formulation comprising a sustained release layer comprising a fat soluble surfactant, a filler and a lubricant, wherein the pH adjusting agent is sodium hydrogen carbonate.
- the formulation is a two-layered tablet having a fast-release layer and a sustained-release layer, which has the advantage of being manufactured by a general purification process without using a fluidized bed coater, but especially since the size of one tablet exceeds 480 mg and its size is very large. Dosing patients or older people may cause significant inconvenience in taking it.
- the problem to be solved by the present invention is to prepare aceclofenac controlled release tablets that can be taken once a day in a simple and inexpensive manufacturing process compared to the prior art, in particular by reducing the size of one tablet significantly to 300 ⁇ 350mg long-term patients It is to provide aceclofenac-containing controlled release tablets that provide an optimal drug dissolution profile to improve the ease of taking for the elderly and to maintain an effective blood concentration during the administration.
- the present invention comprises aceclofenac as an active ingredient, in the controlled release tablet of a multi-layer structure having a fast-release layer and a slow-release layer adjacent to each other,
- the rapid release layer is 25 to 35% by weight of aceclofenac based on the weight of the tablet; 3 to 6 wt% of a disintegrant selected from croscarmellose sodium, crospovidone, and sodium starch glycolate; 10 to 14% by weight of an excipient selected from dimannitol, lactose and microcrystalline cellulose; 0.5 to 1.5% by weight of a binder selected from hydroxypropyl cellulose, povidone, methyl cellulose and gelatin; It consists of 1-2% by weight of lubricant selected from light silicic anhydride, talc, magnesium stearate,
- the sustained release layer is 28 to 38% by weight of acecrofenac based on the weight of the tablet; 6-10% by weight of hypromellose; 0.7-9 wt% polyethylene oxide; 4-7 wt% of poorly soluble excipients selected from microcrystalline cellulose, corn starch, potato starch and wheat starch; 0.5 to 1.5% by weight of a binder selected from hydroxypropyl cellulose, povidone, methyl cellulose and gelatin; It consists of 1 to 2% by weight of a lubricant selected from light silicic anhydride, talc, magnesium stearate,
- the weight of one tablet is 300 ⁇ 350mg, the content of aceclofenac contained herein is characterized in that 200mg.
- Aceclofenac-containing controlled release tablets of the present invention can express sufficient anti-inflammatory analgesic effect by taking only once a day, and particularly, the weight of one tablet is 300-350 mg, which is much smaller in size than conventional sustained-release tablets, and thus the convenience of taking There is an improved effect.
- the controlled release tablet of the present invention is a tablet composed of a two-layer structure of a rapid release layer and a sustained release layer, and can be quickly manufactured at a low cost by using a general high speed mixer and a tableting machine, and realize immediate and continuous drug release after taking It has the effect of maximizing the therapeutic effect.
- FIG. 4 is a graph showing the dissolution test results for Example 2, Comparative Examples 1 and 2.
- FIG. 4 is a graph showing the dissolution test results for Example 2, Comparative Examples 1 and 2.
- Aceclofenac-containing controlled release tablet is composed of a multi-layered structure having a rapid release layer and a sustained release layer adjacent to each other, the rapid release layer is composed of aceclofenac and disintegrants, excipients, binders and lubricants as active ingredients,
- the emissive layer consists of aceclofenac and a sustained release base, excipients, binders and glidants.
- the rapid release layer and the sustained release layer may be formed in a two-layer structure stacked up and down, or may be composed of a three-layer structure in which the rapid release layer is stacked up and down with the sustained release layer as an intermediate layer.
- the controlled release tablet is the weight of one tablet of 300 ⁇ 350mg, the content of the active ingredient aceclofenac is characterized in that the daily effective amount of 200mg.
- the aceclofenac is preferably included so as to be divided by 25 to 35% by weight in the immediate release layer and 28 to 38% by weight in the slow release layer based on the total weight of the tablet.
- the rapid release layer contains aceclofenac 80 ⁇ 110mg
- the slow release layer contains 90 ⁇ 120mg of aceclofenac.
- any one or more selected from croscarmellose sodium, crospovidone, and sodium starch glycolate may be used, and the content thereof is 3 to 6 wt% based on the weight of the tablet.
- any one or more selected from dimannitol, lactose, microcrystalline cellulose the content is 10 to 14% by weight.
- any one or more selected from hydroxypropyl cellulose, povidone, methyl cellulose and gelatin may be used, and the content thereof is 0.5 to 1.5% by weight.
- the lubricant may be any one or more selected from light silicic anhydride, talc, magnesium stearate, and glyceryl behenate, and the content thereof is 1 to 2 wt%.
- croscarmellose sodium is used as a disintegrant, microcrystalline cellulose and di-mannitol as excipients, hydroxypropyl cellulose and povidone as binders, magnesium stearate and hard silicic acid as lubricants.
- the sustained release layer comprises a sustained release base, which is a feature of the present invention, wherein the sustained release substrate includes 6-10 wt% of hypromellose, which is a hydrophilic polymer material, and 0.7-9 wt% of polyethylene oxide.
- the hypromellose uses a viscosity of 4000 cps
- the polyethylene oxide has a molecular weight of 900,000 to 5,000,000.
- the dissolution rate of the active ingredient is too fast to achieve the desired slow release effect, on the contrary the content of the hypromellose If the content is 10% by weight or more, or the content of polyethylene oxide is 9% by weight or more, the dissolution rate of the active ingredient is too slow to obtain an effective release effect after taking.
- the viscosity of the hypromellose is more than 4000cps
- the release rate of the main component is too slow, if less than 4000cps release rate is too fast to obtain a normal release effect.
- the molecular weight of the polyethylene oxide is less than 900,000, the release of the main component occurs too fast, if exceeding 5,000,000 the release of the main component is too slow to obtain the desired sustained release effect.
- Another feature of the present invention is an excipient of the sustained release layer, 4 to 7% by weight of any one or more poorly soluble excipient selected from microcrystalline cellulose, corn starch, potato starch, wheat starch. If a water-soluble excipient such as lactose or dimannitol is used in the sustained release layer, elution proceeds much faster than when the same amount of the poorly soluble excipient is used. Therefore, when water-soluble excipients are used, in order for the present invention to achieve the desired sustained release effect, a larger amount of excipient must be added, or a larger amount of sustained release agent, which is the weight of the tablet itself, which is the object of the present invention. Cause to increase. Therefore, the use of poorly soluble excipients as excipients of the sustained release layer is one of the very important factors that can reduce the size and weight of the controlled release tablet according to the present invention.
- the binder of the sustained release layer may be any one or more selected from hydroxypropyl cellulose, povidone, methyl cellulose, gelatin, the content is 0.5 to 1.5% by weight.
- the lubricant may be used any one or more selected from hard silicic anhydride, talc, magnesium stearate, the content is 1 to 2% by weight.
- microcrystalline cellulose is used as an excipient, hydroxypropyl cellulose as a binder, and magnesium stearate as a lubricant.
- Aceclofenac-containing controlled release tablets according to the present invention can be prepared according to the conventional tableting method for oral administration tablets, but are preferably prepared by a wet method. That is, the rapid release layer composition and the sustained release layer composition are prepared by granulating, drying, and sizing the components included in the rapid release layer and the sustained release layer, respectively, and using the conventional tableting machine, the compositions are two-layer structure or three layers. Tableting into a tablet form of the structure completes the controlled release tablet of the present invention.
- the rapid release layer composition and the sustained release layer composition were prepared by the compositions shown in Tables 1 and 3, respectively, and the tablets were compressed into tablets in which the rapid release layer and the sustained release layer were laminated in a two-layered structure. After that, a conventional film coating base was coated thereon to prepare aceclofenac controlled release tablets according to the present invention.
- 1 of the rapid release layer 2 is an active ingredient, 2 is a disintegrant, 3 is an excipient, 4 is a binder, 5 is a lubricant, 1 is an active ingredient, 2 is a sustained release substrate, 3 is Poorly soluble excipient, 4 represents a binder, 5 represents a lubricant.
- Example 1 Example 2
- Example 3 Content (mg) weight% Content (mg) weight% Content (mg) weight% Immediate release layer 1
- Slow-release layer 1 Aceclofenac 100.0 31.94 100 31.44 100.0 30.95 2 Hypromellose 20.0 6.39 25.0 7.86 30.0 9.26 2 Polyethylene oxide 6.4 2.0
- Example 5 Content (mg) weight% Content (mg) weight% Immediate release layer 1 Aceclofenac 100.0 31.84 100.0 29.23 2 croscarmellose sodium 15.0 4.78 15.0 4.38 3 di-mannitol 20.0 6.37 20.0 5.85 3 Microcrystalline cellulose 20.0 6.37 20.0 5.85 4 povidone K30 2.0 0.64 2.0 0.58 4 hydroxypropyl cellulose 1.0 0.32 1.0 0.29 5 light anhydrous silicic acid 3.0 0.96 3.0 0.88 5 magnesium stearate 2.0 0.64 2.0 0.58 sub Total 163.0 51.89 163.0 47.65 Slow-release layer 1 Aceclofenac 100 31.84 100 29.23 2 Hypromellose 25.0 7.96 25.0 7.31 2 Polyethylene oxide 2.4 0.76 30.4 8.89 3 Microcrystalline cellulose 16.7 5.32 16.7 4.88 4 hydroxypropyl cellulose 3.0 0.96 3.0 0.88 5 magnesium stearate 4.0 1.27 4.0 1.17 sub Total 151.1 48.11 179.
- Example 7 Content (mg) weight% Content (mg) weight% Immediate release layer 1 Aceclofenac 80.0 25.27 110.0 34.49 2 croscarmellose sodium 12.0 3.79 16.5 5.17 3 di-mannitol 16.0 5.05 22.0 6.90 3 Microcrystalline cellulose 16.0 5.05 22.0 6.90 4 povidone K30 1.6 0.51 2.2 0.69 4 hydroxypropyl cellulose 0.8 0.25 1.1 0.34 5 light anhydrous silicic acid 2.4 0.76 3.3 1.03 5 magnesium stearate 1.6 0.51 2.2 0.69 sub Total 130.4 41.20 179.3 56.23 Slow-release layer 1 Aceclofenac 120.0 37.91 90.0 28.22 2 Hypromellose 30.0 9.48 22.5 7.06 2 Polyethylene oxide 7.7 2.43 5.8 1.81 3 Microcrystalline cellulose 20.0 6.33 15.0 4.71 4 hydroxypropyl cellulose 3.6 1.14 2.7 0.85 5 magnesium stearate 4.8 1.52 3.6 1.13 sub Total 186.1
- the immediate release layer composition and the sustained release layer composition were prepared by the composition as shown in Table 4, and the tablets were compressed into tablets in which the rapid release layer and the sustained release layer were laminated in a two-layered structure.
- a conventional film coating base was coated thereon to prepare aceclofenac controlled release tablets according to the present invention.
- lactose and dimannitol which are water-soluble excipients, were used instead of poorly soluble excipients as excipients in the sustained release layer.
- the dissolution test was performed for each of the aceclofenac controlled release tablets prepared according to the above Examples and Comparative Examples, and the results are shown in FIGS. 1 to 4.
- the comparative dissolution test conditions were carried out under the condition of rotating the paddle (paddle) at 50rpm in pH 6.8 eluent by the comparative dissolution test method of the drug equivalence standard.
- the aceclofenac controlled release tablet of the present invention is almost uniform for each time period for 24 hours by the immediate and continuous release of the drug in the immediate release layer and the sustained release layer It was confirmed that the release rate.
- Figures 1 and 2 confirm that the dissolution rate is also proportionally changed by the content of the sustained release substrate hypromellose and polyethylene oxide contained in the sustained release layer. Therefore, by controlling the content of the sustained release substrate, it is possible to prepare a sustained release tablet having various release patterns.
- FIG. 4 shows that when a water-soluble excipient such as lactose or dimannitol is used as an excipient used in the sustained release layer, the drug is rapidly released to obtain a normal sustained release effect. Therefore, in order to increase the normal sustained release effect, an additional excipient or a sustained release agent must be added to the sustained release layer, which causes an increase in the weight of the tablet itself.
- a water-soluble excipient such as lactose or dimannitol
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
구분 | 구성성분 | 실시예 1 | 실시예 2 | 실시예 3 | |||
함량(mg) | 중량% | 함량(mg) | 중량% | 함량(mg) | 중량% | ||
속방출층 | ① 아세클로페낙 | 100.0 | 31.94 | 100.0 | 31.44 | 100.0 | 30.95 |
② 크로스카멜로오스나트륨 | 15.0 | 4.79 | 15.0 | 4.72 | 15.0 | 4.64 | |
③ 디-만니톨 | 20.0 | 6.39 | 20.0 | 6.29 | 20.0 | 6.19 | |
③ 미결정셀룰로오스 | 20.0 | 6.39 | 20.0 | 6.29 | 20.0 | 6.19 | |
④ 포비돈 K30 | 2.0 | 0.64 | 2.0 | 0.63 | 2.0 | 0.62 | |
④ 히드록시프로필셀룰로오스 | 1.0 | 0.32 | 1.0 | 0.31 | 1.0 | 0.31 | |
⑤ 경질무수규산 | 3.0 | 0.96 | 3.0 | 0.94 | 3.0 | 0.93 | |
⑤ 스테아르산마그네슘 | 2.0 | 0.64 | 2.0 | 0.63 | 2.0 | 0.61 | |
소 계 | 163.0 | 52.06 | 163.0 | 51.24 | 163.0 | 50.45 | |
서방출층 | ① 아세클로페낙 | 100.0 | 31.94 | 100 | 31.44 | 100.0 | 30.95 |
② 히프로멜로오스 | 20.0 | 6.39 | 25.0 | 7.86 | 30.0 | 9.26 | |
② 폴리에틸렌옥시드 | 6.4 | 2.04 | 6.4 | 2.01 | 6.4 | 1.98 | |
③ 미결정셀룰로오스 | 16.7 | 5.33 | 16.7 | 5.25 | 16.7 | 5.17 | |
④ 히드록시프로필셀룰로오스 | 3.0 | 0.96 | 3.0 | 0.94 | 3.0 | 0.93 | |
⑤ 스테아르산마그네슘 | 4.0 | 1.28 | 4.0 | 1.26 | 4.0 | 1.24 | |
소 계 | 150.1 | 47.94 | 155.1 | 48.76 | 160.1 | 49.55 | |
합 계 | 313.1 | 100.0 | 318.1 | 100.0 | 323.1 | 100.0 |
division | Ingredient | Example 1 | Example 2 | Example 3 | |||
Content (mg) | weight% | Content (mg) | weight% | Content (mg) | weight% | ||
| ① Aceclofenac | 100.0 | 31.94 | 100.0 | 31.44 | 100.0 | 30.95 |
② croscarmellose sodium | 15.0 | 4.79 | 15.0 | 4.72 | 15.0 | 4.64 | |
③ di-mannitol | 20.0 | 6.39 | 20.0 | 6.29 | 20.0 | 6.19 | |
③ Microcrystalline cellulose | 20.0 | 6.39 | 20.0 | 6.29 | 20.0 | 6.19 | |
④ povidone K30 | 2.0 | 0.64 | 2.0 | 0.63 | 2.0 | 0.62 | |
④ hydroxypropyl cellulose | 1.0 | 0.32 | 1.0 | 0.31 | 1.0 | 0.31 | |
⑤ light anhydrous silicic acid | 3.0 | 0.96 | 3.0 | 0.94 | 3.0 | 0.93 | |
⑤ magnesium stearate | 2.0 | 0.64 | 2.0 | 0.63 | 2.0 | 0.61 | |
sub Total | 163.0 | 52.06 | 163.0 | 51.24 | 163.0 | 50.45 | |
Slow- | ① Aceclofenac | 100.0 | 31.94 | 100 | 31.44 | 100.0 | 30.95 |
② Hypromellose | 20.0 | 6.39 | 25.0 | 7.86 | 30.0 | 9.26 | |
② Polyethylene oxide | 6.4 | 2.04 | 6.4 | 2.01 | 6.4 | 1.98 | |
③ Microcrystalline cellulose | 16.7 | 5.33 | 16.7 | 5.25 | 16.7 | 5.17 | |
④ hydroxypropyl cellulose | 3.0 | 0.96 | 3.0 | 0.94 | 3.0 | 0.93 | |
⑤ magnesium stearate | 4.0 | 1.28 | 4.0 | 1.26 | 4.0 | 1.24 | |
sub Total | 150.1 | 47.94 | 155.1 | 48.76 | 160.1 | 49.55 | |
Sum | 313.1 | 100.0 | 318.1 | 100.0 | 323.1 | 100.0 |
구분 | 구성성분 | 실시예 4 | 실시예 5 | ||
함량(mg) | 중량% | 함량(mg) | 중량% | ||
속방출층 | ① 아세클로페낙 | 100.0 | 31.84 | 100.0 | 29.23 |
② 크로스카멜로오스나트륨 | 15.0 | 4.78 | 15.0 | 4.38 | |
③ 디-만니톨 | 20.0 | 6.37 | 20.0 | 5.85 | |
③ 미결정셀룰로오스 | 20.0 | 6.37 | 20.0 | 5.85 | |
④ 포비돈 K30 | 2.0 | 0.64 | 2.0 | 0.58 | |
④ 히드록시프로필셀룰로오스 | 1.0 | 0.32 | 1.0 | 0.29 | |
⑤ 경질무수규산 | 3.0 | 0.96 | 3.0 | 0.88 | |
⑤ 스테아르산마그네슘 | 2.0 | 0.64 | 2.0 | 0.58 | |
소 계 | 163.0 | 51.89 | 163.0 | 47.65 | |
서방출층 | ① 아세클로페낙 | 100 | 31.84 | 100 | 29.23 |
② 히프로멜로오스 | 25.0 | 7.96 | 25.0 | 7.31 | |
② 폴리에틸렌옥시드 | 2.4 | 0.76 | 30.4 | 8.89 | |
③ 미결정셀룰로오스 | 16.7 | 5.32 | 16.7 | 4.88 | |
④ 히드록시프로필셀룰로오스 | 3.0 | 0.96 | 3.0 | 0.88 | |
⑤ 스테아르산마그네슘 | 4.0 | 1.27 | 4.0 | 1.17 | |
소 계 | 151.1 | 48.11 | 179.1 | 52.35 | |
합 계 | 314.1 | 100.0 | 342.1 | 100.0 |
division | Ingredient | Example 4 | Example 5 | ||
Content (mg) | weight% | Content (mg) | weight% | ||
| ① Aceclofenac | 100.0 | 31.84 | 100.0 | 29.23 |
② croscarmellose sodium | 15.0 | 4.78 | 15.0 | 4.38 | |
③ di-mannitol | 20.0 | 6.37 | 20.0 | 5.85 | |
③ Microcrystalline cellulose | 20.0 | 6.37 | 20.0 | 5.85 | |
④ povidone K30 | 2.0 | 0.64 | 2.0 | 0.58 | |
④ hydroxypropyl cellulose | 1.0 | 0.32 | 1.0 | 0.29 | |
⑤ light anhydrous silicic acid | 3.0 | 0.96 | 3.0 | 0.88 | |
⑤ magnesium stearate | 2.0 | 0.64 | 2.0 | 0.58 | |
sub Total | 163.0 | 51.89 | 163.0 | 47.65 | |
Slow- | ① | 100 | 31.84 | 100 | 29.23 |
② Hypromellose | 25.0 | 7.96 | 25.0 | 7.31 | |
② Polyethylene oxide | 2.4 | 0.76 | 30.4 | 8.89 | |
③ Microcrystalline cellulose | 16.7 | 5.32 | 16.7 | 4.88 | |
④ hydroxypropyl cellulose | 3.0 | 0.96 | 3.0 | 0.88 | |
⑤ magnesium stearate | 4.0 | 1.27 | 4.0 | 1.17 | |
sub Total | 151.1 | 48.11 | 179.1 | 52.35 | |
Sum | 314.1 | 100.0 | 342.1 | 100.0 |
구분 | 구성성분 | 실시예 6 | 실시예 7 | ||
함량(mg) | 중량% | 함량(mg) | 중량% | ||
속방출층 | ① 아세클로페낙 | 80.0 | 25.27 | 110.0 | 34.49 |
② 크로스카멜로오스나트륨 | 12.0 | 3.79 | 16.5 | 5.17 | |
③ 디-만니톨 | 16.0 | 5.05 | 22.0 | 6.90 | |
③ 미결정셀룰로오스 | 16.0 | 5.05 | 22.0 | 6.90 | |
④ 포비돈 K30 | 1.6 | 0.51 | 2.2 | 0.69 | |
④ 히드록시프로필셀룰로오스 | 0.8 | 0.25 | 1.1 | 0.34 | |
⑤ 경질무수규산 | 2.4 | 0.76 | 3.3 | 1.03 | |
⑤ 스테아르산마그네슘 | 1.6 | 0.51 | 2.2 | 0.69 | |
소 계 | 130.4 | 41.20 | 179.3 | 56.23 | |
서방출층 | ① 아세클로페낙 | 120.0 | 37.91 | 90.0 | 28.22 |
② 히프로멜로오스 | 30.0 | 9.48 | 22.5 | 7.06 | |
② 폴리에틸렌옥시드 | 7.7 | 2.43 | 5.8 | 1.81 | |
③ 미결정셀룰로오스 | 20.0 | 6.33 | 15.0 | 4.71 | |
④ 히드록시프로필셀룰로오스 | 3.6 | 1.14 | 2.7 | 0.85 | |
⑤ 스테아르산마그네슘 | 4.8 | 1.52 | 3.6 | 1.13 | |
소 계 | 186.1 | 58.80 | 139.6 | 43.77 | |
합 계 | 316.5 | 100.0 | 318.6 | 100.0 |
division | Ingredient | Example 6 | Example 7 | ||
Content (mg) | weight% | Content (mg) | weight% | ||
| ① Aceclofenac | 80.0 | 25.27 | 110.0 | 34.49 |
② croscarmellose sodium | 12.0 | 3.79 | 16.5 | 5.17 | |
③ di-mannitol | 16.0 | 5.05 | 22.0 | 6.90 | |
③ Microcrystalline cellulose | 16.0 | 5.05 | 22.0 | 6.90 | |
④ povidone K30 | 1.6 | 0.51 | 2.2 | 0.69 | |
④ hydroxypropyl cellulose | 0.8 | 0.25 | 1.1 | 0.34 | |
⑤ light anhydrous silicic acid | 2.4 | 0.76 | 3.3 | 1.03 | |
⑤ magnesium stearate | 1.6 | 0.51 | 2.2 | 0.69 | |
sub Total | 130.4 | 41.20 | 179.3 | 56.23 | |
Slow- | ① Aceclofenac | 120.0 | 37.91 | 90.0 | 28.22 |
② Hypromellose | 30.0 | 9.48 | 22.5 | 7.06 | |
② Polyethylene oxide | 7.7 | 2.43 | 5.8 | 1.81 | |
③ Microcrystalline cellulose | 20.0 | 6.33 | 15.0 | 4.71 | |
④ hydroxypropyl cellulose | 3.6 | 1.14 | 2.7 | 0.85 | |
⑤ magnesium stearate | 4.8 | 1.52 | 3.6 | 1.13 | |
sub Total | 186.1 | 58.80 | 139.6 | 43.77 | |
Sum | 316.5 | 100.0 | 318.6 | 100.0 |
구분 | 구성성분 | 비교예 1 | 비교예 2 | ||
함량(mg) | 중량% | 함량(mg) | 중량% | ||
속방출층 | ① 아세클로페낙 | 100.0 | 31.44 | 100.0 | 31.44 |
② 크로스카멜로오스나트륨 | 15.0 | 4.72 | 15.0 | 4.72 | |
③ 디-만니톨 | 20.0 | 6.29 | 20.0 | 6.29 | |
③ 미결정셀룰로오스 | 20.0 | 6.29 | 20.0 | 6.29 | |
④ 포비돈 K30 | 2.0 | 0.63 | 2.0 | 0.63 | |
④ 히드록시프로필셀룰로오스 | 1.0 | 0.31 | 1.0 | 0.31 | |
⑤ 경질무수규산 | 3.0 | 0.94 | 3.0 | 0.94 | |
⑤ 스테아르산마그네슘 | 2.0 | 0.63 | 2.0 | 0.63 | |
소 계 | 163.0 | 51.24 | 163.0 | 51.24 | |
서방출층 | ① 아세클로페낙 | 100 | 31.44 | 100 | 31.44 |
② 히프로멜로오스 | 25.0 | 7.86 | 25.0 | 7.86 | |
② 폴리에틸렌옥시드 | 6.4 | 2.01 | 6.4 | 2.01 | |
③ 유당 | 16.7 | 5.25 | - | - | |
③ 디 만니톨 | - | - | 16.7 | 5.25 | |
④ 히드록시프로필셀룰로오스 | 3.0 | 0.94 | 3.0 | 0.94 | |
⑤ 스테아르산마그네슘 | 4.0 | 1.26 | 4.0 | 1.26 | |
소 계 | 155.1 | 48.76 | 155.1 | 48.76 | |
합 계 | 318.1 | 100.0 | 318.1 | 100.0 |
division | Ingredient | Comparative Example 1 | Comparative Example 2 | ||
Content (mg) | weight% | Content (mg) | weight% | ||
| ① Aceclofenac | 100.0 | 31.44 | 100.0 | 31.44 |
② croscarmellose sodium | 15.0 | 4.72 | 15.0 | 4.72 | |
③ di-mannitol | 20.0 | 6.29 | 20.0 | 6.29 | |
③ Microcrystalline cellulose | 20.0 | 6.29 | 20.0 | 6.29 | |
④ povidone K30 | 2.0 | 0.63 | 2.0 | 0.63 | |
④ hydroxypropyl cellulose | 1.0 | 0.31 | 1.0 | 0.31 | |
⑤ light anhydrous silicic acid | 3.0 | 0.94 | 3.0 | 0.94 | |
⑤ magnesium stearate | 2.0 | 0.63 | 2.0 | 0.63 | |
sub Total | 163.0 | 51.24 | 163.0 | 51.24 | |
Slow- | ① | 100 | 31.44 | 100 | 31.44 |
② Hypromellose | 25.0 | 7.86 | 25.0 | 7.86 | |
② Polyethylene oxide | 6.4 | 2.01 | 6.4 | 2.01 | |
③ lactose | 16.7 | 5.25 | - | - | |
③ di-mannitol | - | - | 16.7 | 5.25 | |
④ hydroxypropyl cellulose | 3.0 | 0.94 | 3.0 | 0.94 | |
⑤ magnesium stearate | 4.0 | 1.26 | 4.0 | 1.26 | |
sub Total | 155.1 | 48.76 | 155.1 | 48.76 | |
Sum | 318.1 | 100.0 | 318.1 | 100.0 |
Claims (4)
- 아세클로페낙을 유효성분으로 포함하며 서로 인접한 속방출층과 서방출층을 갖는 다층 구조의 방출제어형 정제에 있어서, In a multi-layer controlled release tablet containing aceclofenac as an active ingredient and having a fast-release layer and a slow-release layer adjacent to each other,상기 속방출층은 상기 정제의 중량에 대하여 아세클로페낙 25~35 중량%와; 크로스카멜로오스나트륨, 크로스포비돈, 전분글리콘산나트륨 중에서 선택된 붕해제 3~6 중량%와; 디만니톨, 유당, 미결정셀룰로오스 중에서 선택된 부형제 10~14 중량%와; 히드록시프로필셀룰로오스, 포비돈, 메틸셀룰로오스, 젤라틴 중에서 선택된 결합제 0.5~1.5 중량%와; 경질무수규산, 탈크, 스테아르산마그네슘 중에서 선택된 활택제 1~2 중량%로 이루어지고, The rapid release layer is 25 to 35% by weight of aceclofenac based on the weight of the tablet; 3 to 6 wt% of a disintegrant selected from croscarmellose sodium, crospovidone, and sodium starch glycolate; 10 to 14% by weight of an excipient selected from dimannitol, lactose and microcrystalline cellulose; 0.5 to 1.5% by weight of a binder selected from hydroxypropyl cellulose, povidone, methyl cellulose and gelatin; It consists of 1-2% by weight of lubricant selected from light silicic anhydride, talc, magnesium stearate,상기 서방출층은 상기 정제의 중량에 대하여 아세크로페낙 28~38 중량%와; 히프로멜로스 6~10 중량%와; 폴리에틸렌옥시드 0.7~9 중량%와; 미결정셀룰로오스, 옥수수전분, 감자전분, 밀전분 중에서 선택된 난용성 부형제 4~7 중량%와; 히드록시프로필셀룰로오스, 포비돈, 메틸셀룰로오스, 젤라틴 중에서 선택된 결합제 0.5~1.5 중량%와; 경질무수규산, 탈크, 스테아르산마그네슘 중에서 선택된 활택제 1~2 중량%로 이루어지되,The sustained release layer is 28 to 38% by weight of acecrofenac based on the weight of the tablet; 6-10% by weight of hypromellose; 0.7-9 wt% polyethylene oxide; 4-7 wt% of poorly soluble excipients selected from microcrystalline cellulose, corn starch, potato starch and wheat starch; 0.5 to 1.5% by weight of a binder selected from hydroxypropyl cellulose, povidone, methyl cellulose and gelatin; It consists of 1 to 2% by weight of a lubricant selected from light silicic anhydride, talc, magnesium stearate,상기 정제 한 개의 중량이 300~350mg이고, 여기에 포함된 아세클로페낙의 함량은 200mg인 것을 특징으로 하는 아세클로페낙 함유 방출제어형 정제.The weight of the tablet is 300 ~ 350mg, the content of aceclofenac contained therein is aceclofenac-containing controlled release tablet, characterized in that 200mg.
- 아세클로페낙을 유효성분으로 포함하며 서로 인접한 속방출층과 서방출층을 갖는 다층 구조의 방출제어형 정제에 있어서, In a multi-layer controlled release tablet containing aceclofenac as an active ingredient and having a fast-release layer and a slow-release layer adjacent to each other,상기 속방출층은 정제 전체의 중량에 대하여 아세클로페낙 25~35 중량%와; 크로스카멜로오스나트륨 3~6 중량%와; 디만니톨 5~7 중량%와; 미결정셀룰로오스 5~7 중량%와; 포비돈 0.3~1 중량%와; 히드록시프로필셀룰로오스 0.2~0.5 중량%와; 경질무수규산 0.6~1.2 중량%; 스테아르산마그네슘 0.4~0.8 중량%로 이루어지고,The rapid release layer is 25 to 35% by weight of aceclofenac based on the total weight of the tablet; 3-6% by weight of croscarmellose sodium; 5-7% by weight of dimannitol; 5-7 wt% of microcrystalline cellulose; Povidone 0.3-1 wt%; 0.2 to 0.5% by weight of hydroxypropyl cellulose; Light anhydrous silicic acid 0.6-1.2 wt%; Magnesium stearate 0.4 to 0.8% by weight,상기 서방출층은 정제 전체의 중량에 대하여 아세크로페낙 28~38 중량%와; 히프로멜로스 6~10 중량%와; 폴리에틸렌옥시드 0.7~9 중량%와; 미결정셀룰로오스 4~7 중량%와; 히드록시프로필셀룰로오스 0.5~1.5 중량%와; 스테아르산마그네슘 1~2 중량%로 이루어지되,The sustained release layer is 28 to 38% by weight of acecrofenac based on the total weight of the tablet; 6-10% by weight of hypromellose; 0.7-9 wt% polyethylene oxide; 4-7% by weight of microcrystalline cellulose; 0.5 to 1.5% by weight of hydroxypropyl cellulose; Magnesium stearate is composed of 1-2% by weight,상기 정제 한 개의 중량이 300~350mg 이고, 여기에 포함된 아세크롤페낙의 함량은 200mg인 것을 특징으로 하는 아세클로페낙 함유 방출제어형 정제.The weight of the tablet is 300 ~ 350mg, the content of acecrofenac contained therein is aceclofenac-containing controlled release tablet, characterized in that 200mg.
- 제1항 또는 제2항에 있어서, 상기 히프로멜로오스는 점도가 4000cps인 것을 사용하고, 상기 폴리에칠렌옥시드는 분자량이 900,000~5,000,000인 것을 사용함을 특징으로 하는 아세클로페낙 함유 방출제어형 정제.The aceclofenac-containing controlled release tablet according to claim 1 or 2, wherein the hypromellose has a viscosity of 4000 cps, and the polyethylene oxide has a molecular weight of 900,000 to 5,000,000.
- 제1항 또는 제2항에 있어서, 상기 속방출층에는 아세클로페낙 80~110mg이 포함되고, 상기 서방출층에는 아세클로페낙 90~120mg이 포함된 것을 특징으로 하는 아세클로페낙 함유 방출제어형 정제.The aceclofenac-containing controlled release tablet according to claim 1 or 2, wherein the fast-release layer contains 80-110 mg of aceclofenac and the slow-release layer contains 90-120 mg of aceclofenac.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013011891A MX346466B (en) | 2011-04-13 | 2012-04-12 | Controlled release type tablet containing aceclofenac. |
BR112013026473-0A BR112013026473B1 (en) | 2011-04-13 | 2012-04-12 | TABLET OF CONTROLLED RELEASE TYPE CONTAINING ACCECLOPENAC |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110034022A KR101310099B1 (en) | 2011-04-13 | 2011-04-13 | Controlled-release tablet containing aceclofenac |
KR10-2011-0034022 | 2011-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012141502A2 true WO2012141502A2 (en) | 2012-10-18 |
WO2012141502A3 WO2012141502A3 (en) | 2013-01-03 |
Family
ID=47009839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/002769 WO2012141502A2 (en) | 2011-04-13 | 2012-04-12 | Controlled release type tablet containing aceclofenac |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101310099B1 (en) |
BR (1) | BR112013026473B1 (en) |
MX (1) | MX346466B (en) |
WO (1) | WO2012141502A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102236650B1 (en) * | 2019-04-16 | 2021-04-07 | 한국유나이티드제약 주식회사 | Pharmaceutical Composition Comprising Aceclofenac and Method of Preparing Thereof |
KR102426727B1 (en) | 2020-04-17 | 2022-07-28 | 성균관대학교산학협력단 | oral drug delivery system controlling release rate AND manufacturing method for oral drug delivery system controlling release rate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599529B1 (en) * | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
KR20040077244A (en) * | 2003-02-28 | 2004-09-04 | 한국유나이티드제약 주식회사 | Controlled release pellets for oral and it's manufacturing process |
JP2005232185A (en) * | 2003-03-06 | 2005-09-02 | Astellas Pharma Inc | Medicinal composition for regulating release and process for producing the same |
US20070092573A1 (en) * | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
KR20090022612A (en) * | 2007-08-31 | 2009-03-04 | 주식회사 드림파마 | A novel composition for sustained release-aceclofenac formulation and a method for preparing the same |
KR20100064015A (en) * | 2008-12-04 | 2010-06-14 | 한국유나이티드제약 주식회사 | Controlled-release aceclofenac containing oral drug preparations and it's manufacturing process |
-
2011
- 2011-04-13 KR KR1020110034022A patent/KR101310099B1/en active IP Right Grant
-
2012
- 2012-04-12 WO PCT/KR2012/002769 patent/WO2012141502A2/en active Application Filing
- 2012-04-12 BR BR112013026473-0A patent/BR112013026473B1/en not_active IP Right Cessation
- 2012-04-12 MX MX2013011891A patent/MX346466B/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599529B1 (en) * | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
KR20040077244A (en) * | 2003-02-28 | 2004-09-04 | 한국유나이티드제약 주식회사 | Controlled release pellets for oral and it's manufacturing process |
JP2005232185A (en) * | 2003-03-06 | 2005-09-02 | Astellas Pharma Inc | Medicinal composition for regulating release and process for producing the same |
US20070092573A1 (en) * | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
KR20090022612A (en) * | 2007-08-31 | 2009-03-04 | 주식회사 드림파마 | A novel composition for sustained release-aceclofenac formulation and a method for preparing the same |
KR20100064015A (en) * | 2008-12-04 | 2010-06-14 | 한국유나이티드제약 주식회사 | Controlled-release aceclofenac containing oral drug preparations and it's manufacturing process |
Also Published As
Publication number | Publication date |
---|---|
KR20120116545A (en) | 2012-10-23 |
BR112013026473B1 (en) | 2021-10-13 |
MX346466B (en) | 2017-03-22 |
BR112013026473A2 (en) | 2016-12-20 |
WO2012141502A3 (en) | 2013-01-03 |
KR101310099B1 (en) | 2013-09-23 |
BR112013026473A8 (en) | 2018-01-30 |
MX2013011891A (en) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101612931B1 (en) | Mosapride sustained-release formulation for providing pharmaceutical clinical effects with once-a-day dosing | |
KR20070027560A (en) | Coated tablet formulation and method | |
KR20140085411A (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
KR20070021565A (en) | Pharmaceutical compositions and formulations of Metformin extended release tablets and its preparing method | |
WO2020138791A2 (en) | Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor | |
AU2009265099A1 (en) | Sustained release pharmaceutical compositions comprising Quetiapine | |
KR20120033557A (en) | Immediate-release and sustained-release pharmaceutical composition comprising levodropropizine | |
WO2010026467A2 (en) | Controlled release dosage form of high solubility active ingredient | |
CZ298851B6 (en) | Controlled-release tablet for oral administration of active substances | |
WO2012008675A1 (en) | Sustained-release tablet containing trimebutine | |
WO2012141502A2 (en) | Controlled release type tablet containing aceclofenac | |
WO2018143511A1 (en) | Oral sustained-release triple tablet containing pregabalin | |
WO2004096182A1 (en) | Extended release matrix tablets of carvedilol | |
WO2010024576A2 (en) | Sustained release tablet containing talniflumate with enhanced body absorption | |
CA2717900C (en) | Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles | |
KR20210073285A (en) | Cored Tablet Comprising Proton Pump Inhibitor and Mosapride | |
WO2015108392A1 (en) | Small pharmaceutical tablet containing esomeprazole | |
US20150359795A1 (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
KR101265491B1 (en) | Dissolution rate controlled multilayered tablet for oral administration containing sarpogrelate hydrochloride and manufacturing method thereof | |
KR100795419B1 (en) | Pharmaceutical formulation containing amlodipine and aspirin | |
KR102389339B1 (en) | Controlled release high-dose tamsulosin hydrochloride tablet and its preparing method | |
US8512746B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
WO2012111961A2 (en) | Orally administrated sustained-release tablet containing tianeptine or pharmaceutically acceptable salt thereof | |
KR20210012082A (en) | A pharmaceutical composition comprising mirabegron and tamsulosin | |
KR20190142809A (en) | Pharma ceutical Composition Comprising Cilostazol and Statin derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12770908 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/011891 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013/12118 Country of ref document: TR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12770908 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013026473 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013026473 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131014 |